Member Info for Laura2022

Trellus Health® is commercializing the provision of digital chronic condition management solutions

Trellus' cash position is currently circa £4-5m, with a market cap currently at £1.2m.

Whilst I don't dispute the dire performance in terms of both share price performance and commercial progress, it appears quite clear that Trellus Health's features and capabilities cost a lot more to develop and market compared to the current market cap (shareholders have certainly paid for it!), and even including the possibility of a significant bid premium, not to mention the current cash position, another player could acquire what appears to be very cheap option.

Even a significant premium to the current share price could still be below the cash position, and with some companies in the sector apparently looking for strategic acquisitions that will add new features and capabilities into their products, Trellus could arguably be on certain radars. Particularly as a key benefit of Trellus' methodology is that its condition-agnostic (it can be utilised in management of many more chronic conditions) and Trellus has revealed that they are in discussions with potential partners across all their commercial models, including two later-stage discussions.

The following article provides further food for thought -

Digital health deal count declines in Q3, but check sizes stabilize: Rock Health

Start ups notched just 110 deals in the third quarter, compared with 133 in the second quarter. But average deal size held steady.

Published Oct. 14, 2024

Now, digital health companies are looking to build up their offerings, sometimes through strategic acquisitions, to compete with legacy healthcare firms, according to the latest Rock Health report.

The sector has seen relatively few cases of companies acquiring their competitors this year, a type of M&A that drove increased consolidation in 2021 and 2022.

The above was posted in a TG group today

Wow..what a pipleine of potential work and now we're working directly with CRUK last 12mths

As I said before ..they always do their trades 4pm to 4.30p

Good to see them gone

Bought TRLS too

Can't buy now bunsen

Bought a little

Worth watching

As of 30 June 2024, the Company's net cash position was $8.0m (30 June 2023: $15.8m; 31 December 2023: $12.2m). We have extended our cash runway into late Q3 2025, assuming only current levels of revenue.

 

Outlook

 

Signing the B2B2C agreement with a large US health plan and establishing an active collaboration demonstrated positive commercial progress. The focus is now to enrol patients on the platform as the positive early outcomes from the small number of enrolled patients, have been encouraging to see. Our team and our partner will continue to work hard to ensure further success and the engagement and improvement in health outcomes for people with IBD.

 

Also encouraging has been the exploration of new ways to leverage our methodology and provide value for partners. This has been underlined by our first two licensing agreements with pharmaceutical companies, but securing further partnerships, by enhancing pharmaceutical PSPs, or incorporating resilience assessments within clinical trials, will also be a key focus for the business going forward. A key benefit for us that our methodology is condition-agnostic - whilst IBD is our initial use case, it can be utilised in management of many more chronic conditions, and we are able to adapt quickly to client specifications, and customizing programs at little-to-no additional spend, maximising the opportunity ahead of us.

Whilst no certainty can be given as to the timing or outcome from negotiations, we are in discussions with potential partners across all our commercial models, including two later-stage discussions and we look forward to updating the market as appropriate.

Thanks

Looking great from buying at 23-25

Also intrigued by TRLS...cap £1mln and cash £5mln (albeit reducing l)

Thanks Davey

These are the major holders

https://trellushealth.com/investors

Cash £4mln but market cap only £1.mln ?

Net cash of $8.0m at 30 June 2024 (30 June 2023: $15.8m), with the Company's cash runway further extended into late Q3 2025.

What is happening here please ?

They had only about 20mln left last night

Today been 47mln and now Nt to buy

They are offering nearly 25.5 for 8mln

Yes

He said he would when he changed role...very ethical and unheard of on AIM

Also CC £60k pays for the 2 new roles

Win-win

As we've always said ..PYC have the most modest salaries on AIM

Jim £60k

Pete £70k

Other trash CEOs are taking £200-500k on AIM !!

Leaderboard soon

Moving

20mln volume

Jaari

Why have you started so aggressively having never posted on PYC before?

This one?

Portfolio news

CDD and NovalGen collaborate to advance T cell engager into the clinic

October 2024

Cancer Research UK and NovalGen (link is external)a pioneering clinical stage immunology company, announce a collaboration to bring NovalGen's next generation T cell engager NVG-222 into a first in human clinical trial. NVG-222 is a bispecific T cell engager, targeting ROR1 and CD3, with an in-built autoregulation technology to mitigate toxicity and improve effectiveness for treating people with blood cancer or solid tumours. The trial will be developed, sponsored and managed by our Centre for Drug Development and led by Dr William Townsend at University College London Hospitals(link is external).